Takigawa H, Naruo S, Kanayama H, Kagawa S, Yokoseki H, Inai T, Sumitani H, Sakurai N, Ogawa I, Akazawa S
Dept. of Urology, School of Medicine, University of Tokushima, Japan.
Gan To Kagaku Ryoho. 1996 Jun;23(7):899-903.
In this study, the usefulness of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies, including CDDP, was examined. Granisetron was given to twenty patients with urogenital malignant tumor by iv infusion for thirty minutes after the onset of nausea or vomiting. Nausea disappeared in 15 out of 20 patients (75%), 8 of whom (40%) experienced its disappearance while the granisetron was being administered. Vomiting was perfectly controlled in 5 out of 20 patients (25%) for 24 hours after the granisetron administration. No adverse event seemingly due to granisetron was observed. The result of this study confirmed the speedy effect granisetron on nausea induced by cancer chemotherapy including CDDP, but it stopped short of demonstrating sufficient efficacy for vomiting. Prophylactic use, therefore, seems more desirable in view of the patient's QOL, when a highly emetogenic anti-tumor drug, such as CDDP, is used.
在本研究中，考察了格拉司琼解救疗法对包括顺铂在内的癌症化疗所致恶心和呕吐的有效性。在恶心或呕吐发作后30分钟，对20例泌尿生殖系统恶性肿瘤患者静脉输注格拉司琼。20例患者中有15例（75%）恶心消失，其中8例（40%）在输注格拉司琼时恶心消失。格拉司琼给药后24小时，20例患者中有5例（25%）呕吐得到完全控制。未观察到明显由格拉司琼引起的不良事件。本研究结果证实了格拉司琼对包括顺铂在内的癌症化疗所致恶心的快速疗效，但对呕吐的疗效未达到充分有效。因此，考虑到患者的生活质量，当使用高度致吐的抗肿瘤药物如顺铂时，预防性使用似乎更可取。
